| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO | /s/ Shane Kovacs, Attorney-in-Fact | 14 Jan 2026 | 0001831216 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OLMA | Common Stock | Sale | $283,400 | -10,000 | -6.5% | $28.34 | 144,846 | 12 Jan 2026 | See Footnote | F1, F2 |
| transaction | OLMA | Common Stock | Options Exercise | $243,500 | +50,000 | +9.2% | $4.87 | 592,761 | 13 Jan 2026 | Direct | F3 |
| transaction | OLMA | Common Stock | Sale | $1,374,480 | -49,800 | -8.4% | $27.60 | 542,961 | 13 Jan 2026 | Direct | F4 |
| transaction | OLMA | Common Stock | Sale | $5,698 | -200 | -0.04% | $28.49 | 542,761 | 13 Jan 2026 | Direct | |
| transaction | OLMA | Common Stock | Options Exercise | $243,500 | +50,000 | +9.2% | $4.87 | 592,761 | 14 Jan 2026 | Direct | |
| transaction | OLMA | Common Stock | Sale | $428,914 | -14,997 | -2.5% | $28.60 | 577,764 | 14 Jan 2026 | Direct | F5 |
| transaction | OLMA | Common Stock | Sale | $1,014,737 | -35,003 | -6.1% | $28.99 | 542,761 | 14 Jan 2026 | Direct | F6 |
| holding | OLMA | Common Stock | 12,831 | 12 Jan 2026 | See Footnote | F7 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OLMA | Stock Option (Right to Buy) | Options Exercise | $0 | -50,000 | -33% | $0.000000 | 100,000 | 13 Jan 2026 | Common Stock | 50,000 | $4.87 | Direct | F8 |
| transaction | OLMA | Stock Option (Right to Buy) | Options Exercise | $0 | -50,000 | -50% | $0.000000 | 50,000 | 14 Jan 2026 | Common Stock | 50,000 | $4.87 | Direct | F9 |
| Id | Content |
|---|---|
| F1 | The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F2 | The shares are held by Myles Properties Inc., of which the Reporting Person is President. |
| F3 | On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4. |
| F4 | The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| F5 | The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F6 | The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F7 | The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. |
| F8 | 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| F9 | 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |